EcoDrugPlus

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSNGAG00000023752
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSNGAG00000008127
Gene Symbol: GABBR2
3 Cross references
241 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSNGAG00000014088
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSNGAG00000001369
Gene Symbol: GLP1R
3 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSNGAG00000020783
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSNGAG00000022508
Gene Symbol: GCGR
3 Cross references
183 Possible Orthologues:

Glucokinase

Ensembl ID : ENSNGAG00000022694
Gene Symbol: GCK
3 Cross references
211 Possible Orthologues:

Glucosidase Alpha, Acid

Ensembl ID : ENSNGAG00000016019
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Glucosylceramidase Beta

Ensembl ID : ENSNGAG00000014290
Gene Symbol: GBA
3 Cross references
254 Possible Orthologues:

Glutamate Carboxypeptidase 2

Ensembl ID : ENSNGAG00000012747
Gene Symbol: LOC103750517
3 Cross references
210 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSNGAG00000004680
Gene Symbol: GRIA1
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSNGAG00000016094
Gene Symbol: GRIA2
3 Cross references
321 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).